Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rex Diaz

Podiatrist, Foot & Ankle Surgery Chesapeake, VA Doctor of Podiatric Medicine

NPI 1376578922 CMS profile 244337

725 Volvo Pkwy Ste 210, Chesapeake, VA 23320

Open in the dashboard

General payments

$12,063

235 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rex Diaz of Chesapeake, VA is reported in the CMS Open Payments database as having received $12,063 across 235 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,934 37
2024 General $1,477 27
2023 General $1,191 18
2022 General $886 19
2021 General $1,239 29
2020 General $866 48
2019 General $2,471 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rex Diaz
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Rex Diaz were reported at $3,934. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Rex Diaz Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $2,471 $389 $118–$1,406 $163
2020 $866 $191 $62–$691 $114
2021 $1,239 $329 $104–$1,341 $132
2022 $886 $419 $125–$1,611 $149
2023 $1,191 $377 $128–$1,164 $160
2024 $1,477 $394 $134–$1,168 $164
2025 $3,934 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $5,581 131 payments
  2. LifeNet Health $2,350 13 payments
  3. Kerecis Limited $1,369 10 payments
  4. Misonix Inc $593 44 payments
  5. Bioventus LLC $320 7 payments
  6. Paragon 28, Inc. $246 3 payments
  7. In2Bones USA, LLC $203 4 payments
  8. Integra LifeSciences Corporation $171 2 payments
  9. ConvaTec Inc. $137 1 payment
  10. Linvatec Corporation $136 1 payment
  11. Other $958 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,008 228 payments
  2. Consulting Fee $2,035 2 payments
  3. Travel and Lodging $464 1 payment
  4. Education $317 1 payment
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $240 3 payments
Products named General payments · program years 2019–2025
  1. TheraGenesis Wound Matrix $2,350 13 payments
  2. HOFFMANN Trauma & Extremeties $1,054 29 payments
  3. ALLOGRAFT $1,050 28 payments
  4. BIO4 $922 27 payments
  5. VARIAX Trauma & Extremeties $900 16 payments
  6. Kerecis Omega3 SurgiClose $799 7 payments
  7. HOFFMANN Trauma & Extremeties $673 14 payments
  8. CITREFIX $654 15 payments
  9. VARIAX Trauma & Extremeties $626 18 payments
  10. Kerecis Omega3 Marigen $623 6 payments
  11. Other $15,598 254 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

270

Median for Podiatry: 160

Drug cost

$2,721

Median for Podiatry: $2,368

Branded share of claims

15.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Generic 43 $806
Terbinafine Hcl Generic 25 $344
Methylprednisolone Generic 47 $289
Doxycycline Hyclate Generic 35 $286
Diclofenac Sodium Generic 21 $279
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 23 $263
Gabapentin Generic 44 $244
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 20 $139
Prednisone Generic 12 $71

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 87 billing codes

Paid by Medicare

$117,497

Of which drugs: $3,166

Medicare patients

448

Average age 74

Services billed

2,171

213 women, 235 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 60%
Arthritis 55%
Chronic kidney disease 36%
Ischemic heart disease 33%
Heart failure 30%
COPD 22%
Depression 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 30 99 $76
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 30 106 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

235 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record